Avandel

Avadel Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing differentiated pharmaceutical products that address unmet patient needs. The company's lead product, LUMRYZ, is an extended-release formulation of sodium oxybate approved by the FDA for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. LUMRYZ utilizes Avadel's proprietary Micropump drug delivery technology, which allows for a single bedtime dose, eliminating the need for the middle-of-the-night awakening required by immediate-release formulations. The company is currently focused on the commercial expansion of LUMRYZ and exploring its potential in pediatric populations and other sleep-related indications. Avadel's business strategy centers on leveraging its drug delivery platforms to improve existing therapies and enhance patient outcomes in the sleep medicine space.